Cargando…

The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review

Non-alcoholic fatty liver disease (NAFLD) is currently considered an important component of metabolic syndrome (MetS). The spectrum of NAFLD includes conditions that range from simple hepatic steatosis to non-alcoholic steatohepatitis. NAFLD is correlated with liver-related death and is predicted to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Borém, Luciana M. A., Neto, João F. R., Brandi, Igor V., Lelis, Deborah F, Santos, Sergio H. S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7091617/ https://www.ncbi.nlm.nih.gov/pubmed/29636553 http://dx.doi.org/10.1038/s41440-018-0040-6

Ejemplares similares

Angiotensin II receptor blocker telmisartan attenuates aortic stiffening and remodelling in STZ-diabetic rats
por: Salum, Erik, et al.
Publicado: (2014)

Angiotensin receptor blocker telmisartan suppresses renal gluconeogenesis during starvation
por: Tojo, Akihiro, et al.
Publicado: (2015)

Angiotensin II type 1 receptor blocker telmisartan induces apoptosis and autophagy in adult T‐cell leukemia cells
por: Kozako, Tomohiro, et al.
Publicado: (2016)

An Angiotensin II (Ang II) Type 1 Receptor Blocker, Telmisartan, Improves Insulin Resistance in KK-A(y) Diabetic Mice
por: Takasu, Toshiyuki, et al.
Publicado: (2006)

Angiotensin II receptor blocker telmisartan enhances running endurance of skeletal muscle through activation of the PPAR-δ/AMPK pathway
por: Feng, Xiaoli, et al.
Publicado: (2011)

Potential of angiotensin II receptor blocker telmisartan in reducing mortality among hospitalized patients with COVID-19 compared with recommended drugs
por: Liu, Dengyuan, et al.
Publicado: (2022)

Attenuation of Immune-Mediated Renal Injury by Telmisartan, an Angiotensin Receptor Blocker and a Selective PPAR-γ Activator
por: Hamano, Yuki, et al.
Publicado: (2011)

Angiotensin receptor blocker telmisartan inhibits cell proliferation and tumor growth of cholangiocarcinoma through cell cycle arrest
por: Samukawa, Eri, et al.
Publicado: (2017)

Angiotensin Receptor Blockers Associated Enteropathy-Brief Report
por: Gosai, Neha, et al.
Publicado: (2022)

Connectivity mapping of angiotensin-PPAR interactions involved in the amelioration of non-alcoholic steatohepatitis by Telmisartan
por: Park, Jung Gyu, et al.
Publicado: (2019)

Long-term, up to 18 months, protective effects of the angiotensin II receptor blocker telmisartan on Epirubin-induced inflammation and oxidative stress assessed by serial strain rate
por: Dessì, Mariele, et al.
Publicado: (2013)

Clinical Pharmacogenetics of Angiotensin II Receptor Blockers in Iraq
por: Al-Hussaniy, Hany A., et al.
Publicado: (2023)

Potential of the Angiotensin Receptor Blockers (ARBs) Telmisartan, Irbesartan, and Candesartan for Inhibiting the HMGB1/RAGE Axis in Prevention and Acute Treatment of Stroke
por: Kikuchi, Kiyoshi, et al.
Publicado: (2013)

Telmisartan-induced sprue-like enteropathy: a case report and a review of patients using non-olmesartan angiotensin receptor blockers
por: Mandavdhare, Harshal Surendra, et al.
Publicado: (2017)

The AT1 Receptor Blocker Telmisartan Reduces Intestinal Mucus Thickness in Obese Mice
por: Nickel, Laura, et al.
Publicado: (2022)

Telmisartan, an Antagonist of Angiotensin II Receptors, Accentuates Voltage-Gated Na(+) Currents and Hippocampal Neuronal Excitability
por: Lai, Ming-Chi, et al.
Publicado: (2020)

Angiotensin II Receptor Blockers and Arrhythmias in Ventricular Hypertrophy
por: Salama, Guy
Publicado: (2022)

The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Moretti, Myla E., et al.
Publicado: (2012)

Receptor Interactions of Angiotensin II and Angiotensin Receptor Blockers—Relevance to COVID-19
por: Moore, Graham J., et al.
Publicado: (2021)

Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)
por: Hirata, Takumi, et al.
Publicado: (2013)

Pneumonia Risk and Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Liu, Chia-Lin, et al.
Publicado: (2013)

Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis
por: Lee, Hyun Woo, et al.
Publicado: (2021)

Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
por: Holloway-Kew, Kara L., et al.
Publicado: (2022)

Erratum to “Effect of Telmisartan or Losartan for Treatment of Nonalcoholic Fatty Liver Disease: Fatty Liver Protection Trial by Telmisartan or Losartan Study (FANTASY)”
por: Hirata, Takumi, et al.
Publicado: (2014)

Summertime dosage-dependent hypersensitivity to an angiotensin II receptor blocker
por: Forsdyke, Donald R
Publicado: (2015)

Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta‐blockers in patients hospitalized for acute heart failure
por: Carubelli, Valentina, et al.
Publicado: (2021)

Beneficial effects of losartan or telmisartan on the local hepatic renin-angiotensin system to counter obesity in an experimental model
por: Graus-Nunes, Francielle, et al.
Publicado: (2019)

Onset of Hyperkalemia following the Administration of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker
por: Jun, Hye-Ran, et al.
Publicado: (2021)

Differential Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on COVID-19
por: Su, Lianjiu, et al.
Publicado: (2021)

Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
por: Zhang, Chao, et al.
Publicado: (2021)

Clinical application of angiotensin receptor blockers in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis
por: Li, Yating, et al.
Publicado: (2018)

Visit-to-Visit Variability and Seasonal Variation in Blood Pressure With Single-Pill Fixed-Dose Combinations of Angiotensin II Receptor Blocker/Calcium Channel Blocker and Angiotensin II Receptor Blocker/Diuretic in Hypertensive Patients
por: Shiga, Yuhei, et al.
Publicado: (2015)

Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat
por: Yoshiji, Hitoshi, et al.
Publicado: (2009)

Clinical Profile of Eprosartan: A Different Angiotensin II Receptor Blocker
por: Blankestijn, P. J, et al.
Publicado: (2008)

Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation
por: Naccarelli, Gerald V, et al.
Publicado: (2009)

Angiotensin receptor blockers in heart failure after the ELITE II trial
por: Willenheimer, Ronnie
Publicado: (2000)

Angiotensin II receptor blockers induce autophagy in prostate cancer cells
por: Woo, Yunseo, et al.
Publicado: (2017)

Combination therapy of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease
por: Vasavada, Nina, et al.
Publicado: (2009)

Angiotensin‐Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID‐19
por: Pan, Michael, et al.
Publicado: (2021)

Effect of telmisartan, angiotensin‐converting enzyme inhibition, or both, on proteinuria and blood pressure in dogs
por: Fowler, Brittany L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jadv4d1hqmscf42r56tibrrleq